1390 / 1601
ESTRO IG and Adaptive Course
Parikh Budapest 2018
Results
- Median follow-up for survivors is 21 months.
- Median OS for patients with maxBED10 > 90 and maxBED10 < 90 was 27.8
months vs. 14.8 months (p = 0.005)
- LC at 18 months for patients with maxBED10 > 90 and maxBED10 < 90 was
87% vs 57% (p = 0.007)
- Number of fractions adapted, maxBED and BED of Rx were predictive of survival
on univariate analysis
- No tumor, patient or other therapy factor was related to outcome
Rudra S, Jiang N, Rosenberg S, Olsen J, Lagerwaard F, Bruynzeel
A, Parikh P, Bassetti M, Lee P; ASTRO 2017